Efficacy and safety of lebrikizumab (an anti‐IL‐13 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo‐controlled phase II trial (TREBLE)

• Results Overview

  When combined with topical steroids, lebrikizumab taken every 4 weeks significantly improved eczema symptoms compared to placebo, with similar side effects between groups.

• Study Summary

  Num Participants:

  209

  Study Type:

  Rct

  Control Group:

  Placebo Every 4 Weeks For 12 Weeks Plus Twice Daily Topical Corticosteroids

  Efficacy End Points Treatment:

  {'EASI-50': 82.4}

  Efficacy End Points Control:

  {'EASI-50': 62.3}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  General Adverse Events	Low To Medium	66.7

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  General Adverse Events	Low To Medium	66.0